Reuters
29 Sept 2026, 11:36 UTC · 1h ago
Verdict
Headline leans bearish. We score QURE −0.40 across one claim.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−0.40moderately bearish
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
UniQure's Huntington's treatment did not reach statistical significance in an ongoing early-to-mid-stage trial despite a 44% slowing of disease progression.
Newsaid on Tuesday
More negative than 99% of claims this week
Which stocks this story touches
Continue reading
5 related stories
More negative than 69% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More negative than 69% of ticker scores this week
The company's Huntington's treatment failed to reach statistical significance in a clinical trial despite showing some slowing of disease progression.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
57m ago
—
QURE hasn't traded since this ran. Last close $39.11 (Sep 28); the reaction starts at the next open.
QURE chart →
